Abstract
Oral HDAC Inhibitor HBI8000 in Japanese Patients with Non-Hodgkin Lymphoma (NHL): Phase I Safety and Efficacy Results
Full Text
Sign-in/Register to access full text options
Published version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have